What Is BPC-157?

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a chain of 15 amino acids — derived from a naturally occurring protein found in human gastric juice. First synthesised for laboratory research in the 1990s, it has since become one of the most studied peptides in preclinical science, attracting interest from researchers investigating gastric mucosal repair, tendon and ligament healing, and anti-inflammatory pathways.

In Australia, BPC-157 is not TGA-registered as a therapeutic good, which means it is legally available for research and laboratory purposes. It cannot be sold for human consumption. For researchers sourcing it domestically, it falls outside the prescription drug framework provided it is marketed and purchased strictly for research use.

Why Researchers Are Interested in BPC-157

BPC-157 has been the subject of over 180 peer-reviewed PubMed-listed studies as of 2025, a figure that has grown dramatically from roughly 45 studies in 2020. The research interest spans several mechanisms:

• Gastrointestinal protection: Early research focused on BPC-157’s ability to promote healing in gastric ulcer models, including studies on inflammatory bowel conditions.
• Tendon and ligament repair: A significant body of preclinical work investigates BPC-157’s effect on fibroblast proliferation and collagen synthesis in tendon injury models.
• Gut-brain axis: More recent research has explored signalling pathways between the gut and central nervous system, with BPC-157 emerging as a compound of interest in this area.
• Anti-inflammatory effects: Multiple studies document reduced inflammatory markers in animal models following BPC-157 administration.

It is important to note that virtually all published research on BPC-157 has been conducted in animal models. No large-scale human clinical trials have been completed to date. Researchers should approach this literature with appropriate scientific rigour.

How to Source BPC-157 in Australia

Sourcing research peptides internationally carries meaningful risk for Australian researchers. The Australian Border Force (ABF) actively inspects inbound shipments, and peptides intercepted at the border can be seized without reimbursement. Transit times from overseas suppliers also introduce temperature stability concerns — many peptides are temperature-sensitive and require cold-chain handling during shipping.

Domestic Australian suppliers eliminate both of these problems. Orders are dispatched via local couriers, typically arriving within 2–5 business days, with no exposure to customs clearance risk. A reputable domestic supplier should offer:

• Third-party Certificate of Analysis (CoA) confirming purity — look for a minimum of 98% by HPLC
• Lyophilised (freeze-dried) powder, which offers superior shelf stability over pre-mixed solutions
• Proper cold storage conditions during warehousing
• Clear research-use-only labelling in compliance with Australian regulations

What to Look For in a Quality Supplier

Not all peptide suppliers are equal. When evaluating an Australian supplier, researchers should verify:

• Independent third-party testing: The CoA should come from a laboratory independent of the manufacturer, not an in-house document.
• HPLC purity data: Look for high-performance liquid chromatography results showing purity of 98% or higher.
• Mass spectrometry confirmation: MS data confirms the peptide sequence is correct, not just that the sample is highly pure.
• Transparent manufacturing information: Reputable suppliers will disclose where peptides are synthesised and can provide batch-specific testing data.
• Proper storage and dispatch protocols: Lyophilised peptides should be shipped with desiccant and appropriate temperature management.

Reconstitution and Handling for Research

BPC-157 is typically supplied as a lyophilised powder in sealed vials. For laboratory use, researchers commonly reconstitute it with bacteriostatic water or sterile saline. Standard research protocol recommends adding reconstitution solution slowly to the side of the vial rather than directly onto the powder, then gently swirling — not shaking — to dissolve.

Once reconstituted, BPC-157 solution should be stored refrigerated (2–8°C) and used within 30 days. Unreconstituted lyophilised powder stored at -20°C retains stability for considerably longer. Always follow your institution’s protocols for handling and disposing of research compounds.

Frequently Asked Questions

Is BPC-157 legal in Australia? BPC-157 is legal to purchase in Australia for research and laboratory purposes. It is not TGA-registered as a therapeutic good and cannot be legally sold for human consumption or therapeutic use.

Can I buy BPC-157 without a prescription in Australia? BPC-157 is not currently listed as a Schedule 4 prescription-only medicine in Australia’s Poisons Standard, which means it can be purchased for research use without a prescription, provided it is sourced from a supplier who markets it strictly for research purposes.

What is the difference between BPC-157 and TB-500? BPC-157 and TB-500 (Thymosin Beta-4) are both research peptides with overlapping areas of scientific interest, particularly around tissue repair. They have different amino acid sequences, mechanisms of action, and research profiles. Some researchers study them in combination; others focus on each individually. Both are available domestically in Australia for research use.